X-Ray Cross-Complementing Group 1 and Thymidylate Synthase Polymorphisms Might Predict Response to Chemoradiotherapy in Rectal Cancer Patients

Lamas, María Jesús; Duran, Goretti; Gómez, Antonio; Balboa, Emilia; Anido, Urbano; Bernárdez, Beatriz; Raña-Díez, P.; López, Rafael; Carracedo, Ángel; Barros, Francisco

doi:10.1016/j.ijrobp.2010.09.053

Cited by 29 publications

(26 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there are few studies in Chinese colorectal cancer patients on these two genes. Only several studies conducted in China investigation the association of XRCC1 with chemotherapy response and survival of colorectal cancer, but the results are conflicting (Grimminger et al, 2010;Lamas et al, 2012;Lv et al, 2012). A study conducted in China reported XRCC1 Arg399Gln polymorphisms is associated with the response to oxaliplantin-based chemotherapy and time to progression in advanced colorectal cancer in Chinese population, and patients with G/G genotype showed enhanced respond to chemotherapy compared to those with G/A and A/A genotypes.…”

Section: Discussionmentioning

confidence: 99%

Association Between Polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln Genes and Prognosis of Colorectal Cancer in a Chinese Population

Gan

Li²,

Chen³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Association Between Polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln Genes and Prognosis of Colorectal Cancer in a Chinese Population

Gan

Li²,

Chen³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Rectal cancer represents a common and severe gastrointestinal illness, which has the high risk of locoregional recurrence and the development of distant metastasis (Lamas et al, 2012). Surgery remains the bulwarks of treatment for rectal cancer throughout the world (Rajput and Bullard Dunn, 2007).…”

Section: Introductionmentioning

confidence: 99%

“…Several studies assessed the impact of DNA repair gene polymorphisms on radiotherapy efficacy, especially XRCC-family genes (XRCC1 and XRCC3) and ERCCfamily genes (ERCC1 and ERCC2) polymorphisms (Balboa et al, 2010). Although there are many studies reported that XRCC1, XRCC3, ERCC1 and ERCC2 genes common polymorphisms influence on individual differences of therapeutic efficacy of radiotherapy for rectal cancer, but the results are often not unified (Balboa et al, 2010;Lamas et al, 2012). For example, Lamas et al found X-ray-repair-cross complementing 1 (XRCC1) rs25487 was significantly associated with the response of radiotherapy in rectal cancer while other studies presented not consistent (Balboa et al, 2010;Cecchin et al, 2010;Grimminger et al, 2010;Lamas et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

DNA Repair Gene Polymorphisms Do Not Predict Response to Radiotherapy-Based Multimodality Treatment of Patients with Rectal Cancer: a Meta-analysis

Guo

Yang²,

Pei³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: : A number of association studies have been carried out to investigate the relationship between genetic polymorphisms in DNA repair genes and response to radiotherapy-based multimodality treatment of patients with rectal cancer. However, their conclusions were inconsistent. The objective of the present study was to assess the role of DNA repair gene genetic polymorphisms in predicting genetic biomarkers of the response in rectal cancer patients treated with neoadjuvant chemoradiation. Materials and Methods: Studies were retrieved by searching the PubMed database, Cochrane Library, Embase, and ISI Web of Knowledge. We conducted a meta-analysis to evaluate the association between genetic polymorphisms and the response in rectal cancer treated with neoadjuvant chemoradiation by checking odds ratios (ORs) and 95% confidence intervals (CIs). Results: Data were extracted from 5 clinical studies for this meta-analysis. The results showed that XRCC1 RS25487, XRCC1 RS179978, XRCC3 RS861539, ERCC1 RS11615 and ERCC2 RS13181 were not associated with the response in the radiotherapy-based multimodality treatment of patients with rectal cancer (p>0.05). Conclusions: This study shows that DNA repair gene common genetic polymorphisms are not significantly correlated with the radiotherapy-based multimodality treatment in rectal cancer patients.

show abstract

“…However, other previous reports of associations between GST and DNA-repair allelic variants and clinical outcomes in CRC have been conflicting [6], [11], [33]–[35]. Whether these conflicting findings have been due to tissue-specific differences in gene expression between colonic and rectal tumors is unclear [36] because reports of stratified analyses based on the site of the CRC tumor are scant.…”

Section: Introductionmentioning

confidence: 99%

Tumor Site- and Stage-Specific Associations between Allelic Variants of Glutathione S-Transferase and DNA-Repair Genes and Overall Survival in Colorectal Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy

et al. 2013

View full text Add to dashboard Cite

IntroductionOur retrospective cohort study investigated the effect of tumor site and stage on the associations between the allelic variants of glutathione S-transferase (GST) and DNA-repair genes and overall survival (OS) in CRC patients treated with 5-fluorouracil (5-FU)-based adjuvant chemotherapy.Material and MethodsWe genotyped GSTM1, GSTT1, GSTP1 Ile105Val, XRCC1 Arg399Gln, XRCC3 Thr241Met, and XPD Lys751Gln in 491 CRC patients between 1995 and 2001. A Cox proportional-hazards model was used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the relationships between the allelic variants and OS. Survival analyses were performed for each allelic variant by using the log-rank test and Kaplan-Meier analysis.ResultsThe CRC patients with the XPD Gln allelic variants had poorer survival than patients with the Lys/Lys genotype (HR = 1.38, 95% CI = 1.02–1.87), and rectal cancer patients had the poorest survival among them (HR = 1.87, 95% CI = 1.18–2.95). A significantly shorter OS was observed among stage II/III colon cancer patients with the XRCC1 Gln allelic variants (HR = 1.69, 95% CI = 1.06–2.71), compared to those with XRCC1 Arg/Arg genotype. In the combined analysis of the XRCC1 and XPD genes patients with stage II/III tumors, the poorest OS occurred in colon cancer patients with the XRCC1 Gln and XPD Gln allelic variants (HR = 2.60, 95% CI = 1.19–5.71) and rectal cancer patients with the XRCC1 Arg/Arg and XPD Gln allelic variants (HR = 2.77, 95% CI = 1.25–6.17).ConclusionThe XPD and XRCC1 allelic variants may be prognostic markers for CRC patients receiving 5-FU based chemotherapy. The contributions of the XPD and XRCC1 allelic variants to OS are tumor site- and/or stage-dependent.

show abstract

X-Ray Cross-Complementing Group 1 and Thymidylate Synthase Polymorphisms Might Predict Response to Chemoradiotherapy in Rectal Cancer Patients

Cited by 29 publications

References 27 publications

Association Between Polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln Genes and Prognosis of Colorectal Cancer in a Chinese Population

Association Between Polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln Genes and Prognosis of Colorectal Cancer in a Chinese Population

DNA Repair Gene Polymorphisms Do Not Predict Response to Radiotherapy-Based Multimodality Treatment of Patients with Rectal Cancer: a Meta-analysis

Tumor Site- and Stage-Specific Associations between Allelic Variants of Glutathione S-Transferase and DNA-Repair Genes and Overall Survival in Colorectal Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy

Contact Info

Product

Resources

About